- Regenxbio (NASDAQ:RGNX) will receive a milestone payment of $80M from Novartis (NYSE:NVS) based upon the achievement of $1B in cumulative net sales of Zolgensma. The company expects to recognize this revenue in Q3 2020.
- "Zolgensma is a transformative, one-time gene therapy for the treatment of pediatric patients with SMA, a debilitating and potentially deadly disease, and the first approved gene therapy based on REGENXBIO's NAV Technology," said Kenneth T. Mills, President and CEO.
- https://seekingalpha.com/news/3626358-regenxbio-earns-80m-milestone-from-novartis
Tuesday, October 27, 2020
Regenxbio earns $80M milestone from Novartis
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.